Glucocorticoid receptor cofactors as therapeutic targets

Current Opinion in Pharmacology

Volumn 10, Issue 6, 2010, Pages 613-619

  Simons, S Stoney ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BETA CATENIN; BICOID; BRCA1 PROTEIN; GENE PRODUCT; GLUCOCORTICOID RECEPTOR; HOX PROTEIN; INTERLEUKIN 1BETA; MIFEPRISTONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN B2M; PROTEIN NKX3 1; PROTEIN PP1 ALPHA; PROTEIN SKA2; SMALL INTERFERING RNA; THYROID RECEPTOR BETA 2; UNCLASSIFIED DRUG;

BINDING AFFINITY; CONCENTRATION RESPONSE; DEPHOSPHORYLATION; DNA BINDING; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; HORMONE ACTION; HORMONE BINDING; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; CELL LINE; CO-REPRESSOR PROTEINS; DRUG PARTIAL AGONISM; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; NUCLEAR RECEPTOR COACTIVATORS; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 78149495249     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.08.001     Document Type: Review

References (60)

1. Munck A., Holbrook N.J. Glucocorticoid-receptor complexes in rat thymus cells. Rapid kinetic behavior and a cyclic model. J Biol Chem 1984, 259:820-831.
2. Simons S.S. How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Curr Top Med Chem 2006, 6:271-285.
3. Simons S.S. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. Bioessays 2008, 30:744-756.
4. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378:681-689.
5. Perissi V., Rosenfeld M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005, 6:542-554.
6. Estebanez-Perpina E., Arnold A.A., Nguyen P., Rodrigues E.D., Mar E., Bateman R., Pallai P., Shokat K.M., Baxter J.D., Guy R.K., et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A 2007, 104:16074-16079.
7. Parent A.A., Gunther J.R., Katzenellenbogen J.A. Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem 2008, 51:6512-6530.
8. Hwang J.Y., Arnold L.A., Zhu F., Kosinski A., Mangano T.J., Setola V., Roth B.L., Guy R.K. Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem 2009, 52:3892-3901.
9. Lonard D.M., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators and human disease. Endocr Rev 2007, 28:575-587.
10. Nagy L., Schwabe J.W. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004, 29:317-324.
11. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006, 20:1405-1428.
12. Kim Y., Sun Y., Chow C., Pommier Y.G., Simons S.S. Effects of acetylation, polymerase phosphorylation, and DNA unwinding in glucocorticoid receptor transactivation. J Steroid Biochem Mol Biol 2006, 100:3-17.
13. Szapary D., Huang Y., Simons S.S. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor regulated gene expression. Mol Endocrinol 1999, 13:2108-2121.
14. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., Katzenellenbogen J.A., Agard D.A., Greene G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002, 9:359-364.
15. Cho S., Kagan B.L., Blackford J.A., Szapary D., Simons S.S. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9. Mol Endocrinol 2005, 19:290-311.
16. Lonard D.M., O'Malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007, 27:691-700.
17. Gregor T., Tank D.W., Wieschaus E.F., Bialek W. Probing the limits to positional information. Cell 2007, 130:153-164.
18. Reinitz J. Developmental biology: a ten per cent solution. Nature 2007, 448:420-421.
19. Reichardt H.M., Umland T., Bauer A., Kretz O., Schutz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol 2000, 20:9009-9017.
20. Luo M., Simons S.S. Modulation of glucocorticoid receptor induction properties by cofactors in peripheral blood mononuclear cells. Hum Immunol 2009, 70:785-789.
21. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 2009, 23:572-583.
22. Bland M.L., Fowkes R.C., Ingraham H.A. Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol Endocrinol 2004, 18:941-952.
23. Song L.-N., Huse B., Rusconi S., Simons S.S. Transactivation specificity of glucocorticoid vs. progesterone receptors: role of functionally different interactions of transcription factors with amino- and carboxyl-terminal receptor domains. J Biol Chem 2001, 276:24806-24816.
24. Szapary D., Song L.-N., He Y., Simons S.S. Differential modulation of glucocorticoid and progesterone receptor transactivation. Mol Cell Endocrinol 2008, 283:114-126.
25. He Y., Blackford J.A., Kohn E.C., Simons S.S. STAMP alters the growth of transformed and ovarian cancer cells. BMC Cancer 2010, 10:128.
26. Wang Q., Blackford J.A., Song L.-N., Huang Y., Simons S.S. Equilibrium interactions of corepressors and coactivators modulate the properties of agonist and antagonist complexes of glucocorticoid receptors. Mol Endocrinol 2004, 18:1376-1395.
27. Ronacher K., Hadley K., Avenant C., Stubsrud E., Simons S.S., Louw A., Hapgood J.P. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 2009, 299:219-231.
28. Wu Y., Kawate H., Ohnaka K., Nawata H., Takayanagi R. Nuclear compartmentalization of N-CoR and its interactions with steroid receptors. Mol Cell Biol 2006, 26:6633-6655.
29. Yoon H.G., Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 2006, 20:1048-1060.
30. Cheng X., Kao H.Y. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation. J Biol Chem 2009, 284:36395-36404.
31. Wang D., Wang Q., Awasthi S., Simons S.S. Amino-terminal domain of TIF2 is involved in competing for corepressor binding to glucocorticoid and progesterone receptors. Biochemistry 2007, 48:8036-8049.
32. Madauss K.P., Grygielko E.T., Deng S.J., Sulpizio A.C., Stanley T.B., Wu C., Short S.A., Thompson S.K., Stewart E.L., Laping N.J., et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007, 21:1066-1081.
33. Song L.N., Gelmann E.P. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 2005, 280:37853-37867.
34. Ai J., Wang Y., Dar J.A., Liu J., Liu L., Nelson J.B., Wang Z. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 2009, 23:1963-1972.
35. Yang J., Singleton D.W., Shaughnessy E.A., Khan S.A. The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization. Mol Cell Endocrinol 2008, 295:94-100.
36. Ma Y., Fan S., Hu C., Meng Q., Fuqua S.A., Pestell R.G., Tomita Y.A., Rosen E.M. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol 2010, 24:76-90.
37. Rice L., Waters C.E., Eccles J., Garside H., Sommer P., Kay P., Blackhall F.H., Zeef L., Telfer B., Stratford I., et al. Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. J Endocrinol 2008, 198:499-509.
38. Belikov S., Astrand C., Wrange O. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. Mol Cell Biol 2009, 29:5413-5425.
39. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., Adcock I.M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006, 203:7-13.
40. Abdel-Hafiz H., Dudevoir M.L., Horwitz K.B. Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. J Biol Chem 2009, 284:9099-9108.
41. Daniel A.R., Qiu M., Faivre E.J., Ostrander J.H., Skildum A., Lange C.A. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 2007, 72:188-201.
42. Suh J.H., Shong M., Choi H.S., Lee K. CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction. Mol Endocrinol 2008, 22:33-46.
43. Ma Q., Fu W., Li P., Nicosia S.V., Jenster G., Zhang X., Bai W. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009, 23:213-225.
44. Xie Y.B., Nedumaran B., Choi H.S. Molecular characterization of SMILE as a novel corepressor of nuclear receptors. Nucleic Acids Res 2009, 37:4100-4115.
45. Herdick M., Bury Y., Quack M., Uskokovic M.R., Polly P., Carlberg C. Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. Mol Pharmacol 2000, 57:1206-1217.
46. Wan W., Farboud B., Privalsky M.L. Pituitary resistance to thyroid hormone syndrome is associated with T3 receptor mutants that selectively impair beta2 isoform function. Mol Endocrinol 2005, 19:1529-1542.
47. Kamashev D., Vitoux D., De The H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004, 199:1163-1174.
48. Chen S., Kesler C.T., Paschal B.M., Balk S.P. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem 2009, 284:25576-25584.
49. Chen W., Dang T., Blind R.D., Wang Z., Cavasotto C.N., Hittelman A.B., Rogatsky I., Logan S.K., Garabedian M.J. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 2008, 22:1754-1766.
50. Laenger A., Lang-Rollin I., Kozany C., Zschocke J., Zimmermann N., Ruegg J., Holsboer F., Hausch F., Rein T. XAP2 inhibits glucocorticoid receptor activity in mammalian cells. FEBS Lett 2009, 583:1493-1498.
51. Zhu P., Baek S.H., Bourk E.M., Ohgi K.A., Garcia-Bassets I., Sanjo H., Akira S., Kotol P.F., Glass C.K., Rosenfeld M.G., Rose D.W. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006, 124:615-629.
52. Ni L., Yang C.S., Gioeli D., Frierson H., Toft D.O., Paschal B.M. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol 2010, 30:1243-1253.
53. Morin B., Nichols L.A., Holland L.J. Flanking sequence composition differentially affects the binding and functional characteristics of glucocorticoid receptor homo- and heterodimers. Biochemistry 2006, 45:7299-7306.
54. Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009, 324:407-410.
55. Tchen C.R., Martins J.R., Paktiawal N., Perelli R., Saklatvala J., Clark A.R. Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J Biol Chem 2010, 285:2642-2652.
56. Liu W., Wang J., Yu G., Pearce D. Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Mol Endocrinol 1996, 10:1399-1406.
57. Connaghan-Jones K.D., Heneghan A.F., Miura M.T., Bain D.L. Thermodynamic analysis of progesterone receptor-promoter interactions reveals a molecular model for isoform-specific function. Proc Natl Acad Sci U S A 2007, 104:2187-2192.
58. Ong K.M., Blackford J.A., Kagan B.L., Simons S.S., Chow C.C. A new theoretical framework for gene induction and experimental comparisons. Proc Natl Acad Sci U S A 2010, 107:7107-7112.
59. He Y., Simons S.S. STAMP: a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 2007, 27:1467-1485.
60. Tao Y.-G., Xu Y., Xu H.E., Simons S.S. Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Biochemistry 2008, 47:7648-7662.